Impact of clomiphene on semen parameters in normogonadotrophic idiopathic male infertility: a double-blind randomised placebo-controlled trial

Hudson Institute of Medical Research0 个研究点目标入组 32 人开始时间: 2023年3月29日最近更新: 2024年9月9日

适应症

试验速览

暂无简介。

•1) Men of heterosexual couples with at least 12 months of infertility
•2) Aged 18-50 years at enrolment
•3) Able to provide informed consent in English
•4) Have at least two semen analysis in the preceding 6 months showing oligozoospermia (<10 million/ml or total count <26 million)

•Azoospermia
•BMI >= 35 kg/m2
•Serum FSH >8.4 IU/L
•Morning serum total testosterone <8 nmol/L
•Serum oestradiol >160 pmol/L
•Any genetic or endocrine disorder known to cause infertility (e.g. Prader-Willi, hyperprolactinaemia, Yq deletion, hypogonadotrophic hypogonadism).
•Any medications within the prior 6 months known to disrupt the hypothalamic-pituitary gonadal axis, e.g. testosterone, aromatase inhibitors, opioids.
•History of testicular cancer or surgery, untreated cryptorchidism, previous chemotherapy, or pelvic irradiation, large or clinically significant varicocele, prior vasectomy.
•Current genitourinary tract infection or seminal white cell count >1 mill/ml
•Sperm antibodies >50% bound (excluding tail-tip only)
•Retrograde ejaculation
•Systemic severe chronic disease (e.g. severe kidney or liver disease)
•Current smoker
•Alcohol abuse >20 standard drinks per week

发起方